Steve van Os

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · European Urology · 2016 · 419 citations · Full text

Medicine, Oncology, Pharmacology +13

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

Peter Kenemans, N.J. Bundred, Jean-Michel Foidart et al. · The Lancet Oncology · 2009 · 332 citations · Full text

Medicine, Oncology, Pharmacology +10

Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

Neal D. Shore, Simon Chowdhury, Arnauld Villers et al. · The Lancet Oncology · 2016 · 283 citations

Medicine, Oncology, Pharmacology +14

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Andrew J. Armstrong, Ping Lin, Bertrand Tombal et al. · European Urology · 2020 · 163 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women

Pierre D. Delmas, Susan R. Davis, J. Hensen et al. · Osteoporosis International · 2008 · 46 citations

Medicine, Endocrinology, Pharmacotherapy +14